Johnson & Johnson (JNJ)

129.67
0.13 0.10
NYSE : Health Technology
Prev Close 129.54
Open 129.60
Day Low/High 129.11 / 130.50
52 Wk Low/High 121.00 / 148.99
Volume 5.00M
Avg Volume 7.30M
Exchange NYSE
Shares Outstanding 2.64B
Market Cap 344.23B
EPS 5.70
P/E Ratio 21.05
Div & Yield 3.80 (2.84%)
Jim Cramer: The Fed's Dramatic Sea Change and What It Means for Stocks Now

Jim Cramer: The Fed's Dramatic Sea Change and What It Means for Stocks Now

The best stocks to buy in this environment are the ones that have the greatest growth.

How to Play the Fed's Gift to the Markets (One Way Is With Netflix)

How to Play the Fed's Gift to the Markets (One Way Is With Netflix)

Wednesday was the first day that Netflix traded on above-average volume since Jan. 24.

The Rally in Johnson & Johnson Looks Like it has Run Its Course

The Rally in Johnson & Johnson Looks Like it has Run Its Course

Let's check out the charts.

Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult

Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult

Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.

Digging Down on the Dow 30

Digging Down on the Dow 30

Just 13 of the 30 Dow components are in clear uptrends.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary

Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary

Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.

The Charts of Johnson & Johnson Do Not Yet Convince Me of the Bull Case

The Charts of Johnson & Johnson Do Not Yet Convince Me of the Bull Case

Let's look at the charts and indicators to round out the picture.

Jim Cramer: This Market Has a Terrible Case of Attention Deficit Disorder

Jim Cramer: This Market Has a Terrible Case of Attention Deficit Disorder

I think this truly defines what has gone on with tech stocks since the latest reporting period began.

How Are My Ideas Working Out? January Trade Review (Part 1)

How Are My Ideas Working Out? January Trade Review (Part 1)

Eight of these 11 trade ideas are in the green, with a few big winners.

Jim Cramer: This Strong Dollar Is Biting Deeply Into Apple

Jim Cramer: This Strong Dollar Is Biting Deeply Into Apple

Dollar strength is affecting the competitive advantage of U.S. companies around the globe, and it is a more insidious problem that most people recognize.

The New Small Biotechs Heating Up the Medical Cannabis Space

The New Small Biotechs Heating Up the Medical Cannabis Space

These companies are working to plant their flag in a new landscape.

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

How to Play Johnson & Johnson Now That Earnings Are Out

How to Play Johnson & Johnson Now That Earnings Are Out

There's a lot of runway left to adjust guidance numbers moving forward.

My Greatest Concern About Procter & Gamble Heading Into Earnings

My Greatest Concern About Procter & Gamble Heading Into Earnings

Volatility appears to be the most attractive play during the early portion of earnings season.

Two Sticking Points With Johnson & Johnson: Guidance and Litigation Expense

Two Sticking Points With Johnson & Johnson: Guidance and Litigation Expense

While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.

Johnson & Johnson: How the Stock Looks on the Charts After Earnings

Johnson & Johnson: How the Stock Looks on the Charts After Earnings

Experienced traders could approach the long side carefully.

The Meat and Potatoes of This Global Economic Slowdown: Market Recon

The Meat and Potatoes of This Global Economic Slowdown: Market Recon

It's centered around a few themed negatives, all forcing their own various uncertainties into free market price discovery.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

A Johnson & Johnson Volatility Trade

A Johnson & Johnson Volatility Trade

JNJ's current pennant pattern creates the potential for a big move in the month of January.

Johnson & Johnson Stock May Take a While to Rebound From Talc Hit

Johnson & Johnson Stock May Take a While to Rebound From Talc Hit

Shares have fallen hard, despite the company's vehement scientific and legal defense.

Johnson & Johnson Remains Dividend Stock Royalty

Johnson & Johnson Remains Dividend Stock Royalty

Despite recent talc powder risks, the long-term earnings power of this 'Dividend King' has not deteriorated.

Jim Cramer: This Is a Treacherous Bear Market

Jim Cramer: This Is a Treacherous Bear Market

But even in bear markets you get spikes, usually short sharp ones.

It's Ugly Out There: Here's What I Suggest Traders Do Right Now

It's Ugly Out There: Here's What I Suggest Traders Do Right Now

We are absolutely due for a rip-your-face-off rally in the wake of entering a bear market.

Now Is the Time to Play Defense

Now Is the Time to Play Defense

Remember, though, playing defense is very different than leaving the stadium altogether.

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

These are currently situations where companies are facing serious lawsuits.

Are Algos Jumping on J&J Headlines?

Are Algos Jumping on J&J Headlines?

Are machines jumping on Johnson & Johnson's human risk headlines?

Chart of the Day: Johnson & Johnson's Punishment Appears Overdone

Chart of the Day: Johnson & Johnson's Punishment Appears Overdone

Putting J&J stock's selloff in a graphic illustrates the market's swift and violent reaction to the Reuters report.